Genetic Testing Market: Information by Type (Carrier Testing, Diagnostic Testing), Technology (Cytogenetic Testing, Molecular Testing), Application, and Region— Forecast Till 2026

Dec 30, 2019   Global Statistics Representing Genetic Testing Market Scenario Genetic testing market is majorly driven by the increasing prevalence of genetic disorders, oncology, and rare disease. Today, the growing demand for genetic data for the discovery of new therapies such as personalized medicine and targeted drugs are offering lucrative opportunities for the market growth.   Global genetic testing market was valued at USD 7,902 million in 2018 and is expected to grow at a CAGR of 11.8% during t...
Request Free Sample Report

Report Description

Global Statistics Representing Genetic Testing Market Scenario

Genetic testing market is majorly driven by the increasing prevalence of genetic disorders, oncology, and rare disease. Today, the growing demand for genetic data for the discovery of new therapies such as personalized medicine and targeted drugs are offering lucrative opportunities for the market growth.  

Global genetic testing market was valued at USD 7,902 million in 2018 and is expected to grow at a CAGR of 11.8% during the forecast period.

What are the benefits of genetic testing?

‘Human Genome Project’ and advancements in computer technology are unraveling umpteen underlying genes related mysteries and is paving to be a blessing in the diagnosis of life-threating diseases, including genetic mutation, and cancer, among others. In line with the growing popularity, several players  are investing heavily in the genetic diagnostic for the detection of different types of cancer. For instance, Grail—a spin-off of Illumina—is working on detecting different types of cancer with a simple blood test and has received over USD 1.5 billion funding from various sources, including renowned companies like Amazon and Microsoft. Additionally, many research institutes are actively working on developing related tests. For instance, recently, Johns Hopkins University school of medicine developed a CancerSEEK test that can detect about 8 different types of cancer.

Genetic Testing: A Beginning of Personalized Medicine Era

Today, genomic data—when integrated with data analytics tools—have the potential to fulfill the data needs for personalized medicine research. Moreover, next-generation sequencing is becoming a revolutionary technology among the academic and clinical research practices, which is further creating umpteen potential opportunities for the diagnostic test service providers and the pharmaceutical companies in discovering new therapies. For instance, 23andMe, a genomics biotechnology company, offers ancestry related tests to the customers. The company has a choice to sell this data for biomedical research. In 2018, GlaxoSmithKline plc. and 23andMe entered into an agreement to identify novel drug targets. In addition, GlaxoSmithKline plc. made an equity investment of USD 300 million in 23andMe. Similarly, Flatiron Health and Foundation Medicine’s Clinico-Genomic Database offers genomic data of over 120,000 cancer patients.  

Increasing Prevalence of Genetic Disorders

Globally, the prevalence of several rare diseases is growing at a concerning. Currently, around 400 million people are suffering from different rare diseases across the globe. As per the Global Genes, about 8 in 10 rare diseases are caused due to the faulty gene and there are around 7,000 types of rare disease and genetic disorders across the globe. In the U.K alone, about 30,000 children and babies are diagnosed with a certain type of genetic disorder, Genetic Disorders U.K. Whereas, in the U.S., birth defects affects 1 in every 33 babies (about 3% of all babies) every year. As per CDC, birth defect is one of the leading cause of infant deaths, accounting for about 20% of total infant deaths across the globe. Some of the most common inherited disorders include sickle cell disease, and thalassemia, among others. In the U.S., sickle cell disease affects around 100,000 Americans, the CDC. Its average medical expenditure is estimated to be USD 11,702, with medical coverage of USD 14,772 for children. 

Intended Audience

  • Genetic Test Manufacturers and Suppliers
  • Pharmaceutical Companies
  • Hospitals
  • Research Institutes
  • Regulatory Bodies

Diagnostic Testing to Account for a Large Share of the Pie

In the report, we have provided a detailed analysis of the genetic testing information, including carrier testing, diagnostic testing, newborn screening, and prenatal testing. The diagnostic testing captures a larger share of the global genetic testing market. This can be attributed to the increasing prevalence of genetic disorders across the globe. As per the American Society for Reproductive Medicine, birth defects are prevalent in 1 in every 20 pregnancies. That is why, the screening of the genetic diseases are performed extensively in the developed nations for reducing the prevalence of birth defects. Preimplantation genetic diagnosis is one such technique that tests embryos for genetic disorders before in vitro fertilization. In line with this, several market players are collaborating on developing advanced preimplantation genetic diagnosis. Recently, in 2019, Vitrolife received the distribution rights of Illumina’s (PGT-A) kit VeriSeq that is used in the preimplantation genetic testing for aneuploidy. Vitrolife is targeting the Americas, Europe, and the Middle East and Africa for selling its product.

North America Will Remain the Most Prominent Market Due To Well Established Healthcare Infrastructure  

North America is dominating the global genetic testing market and will continue the same during the forecast period. This can be attributed to the well-established healthcare infrastructure, defined regulatory framework, and high adoption of genetic tests. The U.S. alone has the presence of gigantic genetic testing laboratories that are offering high-end services to the customers. Additionally, increasing partnership among the players is adding fuel to the market growth. In September 2019, ARCHIMEDlife and Blueprint Genetics partnered in North America—ARCHIMEDlife Medical Laboratory offers biochemical and genetic testing for rare diseases—to increase the range of genetic testing services in North America.  

Europe to Rank Second in the Genetic Testing Market

Europe has the second largest genetic testing market. In the region, the healthcare service varies as per the geographical coverage, population density, and government policies. The governments in the region are actively participating in increasing the adoption of genetic testing across the healthcare sector. For instance, recently, the European Commission-funded EuroGentest—a genetic testing project—that aims at standardizing the process of genetic testing, and provide high-quality, accurate, and reliable results. However, many countries are still grappling with strict regulations of genetic testing. For instance, Germany’s Genetic Diagnostics Act regulates both predictive and diagnostic genetic testing. Furthermore, the involvement of physicians is required for direct to home genetic services (DTC GT), the European Academies Science Advisory Council (EASAC). Globally, the changing regulatory scenario and increasing government participation for the promotion of genetic testing are driving the market growth. For instance, France and the U.K.  are planning to build sequencing facilities, and are creating databases for integrating the genetic testing results into healthcare. Recently, the U.K. announced to sequence around 5 million genomes in the next five years. In addition to this, around 13 new centers were launched in the U.K. in 2019, which offered whole-genome sequencing for people suffering from cancer and autism.

Genetic Testing Industry  is Growing in Asia-Pacific  

In Asia Pacific, Japan is leading the genetic testing industry. The country’s genetic industry is backed with the presence of personalized nutrition firms that are offering several tailored products for the elderly population. The GENESIS HEALTHCARE and Genequest Inc. are two dominating companies in the genetic testing industry. Moreover, the number of newborns with birth defects has increased subsequently in the last few years, which is further adding fuel to the market growth. For instance, birth defects in Thailand, Indonesia, and India accounts for around 21%, 19%, and 19.5% , respectively.

Key Players

Some of the key players in the global genetic testing market are Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Precipio, Myriad Genetics, Inc., Luminex Corporation, F. Hoffmann-La Roche Ltd, Danaher, Bio-Rad Laboratories, Inc.,  Abbott, and 23andMe, Inc.

Global Genetic Testing  Market: Segmentation

By Type

  • Carrier Testing
  • Diagnostic Testing
  • Newborn Screening
  • Predictive and Presymptomatic Testing
  • Prenatal Testing
  • Other Types

By Technology

  • Cytogenetic Testing
  • Biochemical Testing
  • Molecular Testing

By Application

  • Alzheimer’s Disease
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Duchenne Muscular Dystrophy
  • Thalassemia
  • Huntington’s Disease
  • Rare Diseases
  • Other Diseases

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

What the Report Covers

  • In-depth analysis of market dynamics, including drivers, restraints, and opportunities
  • Quantitative analysis of the current market
  • Prevailing market opportunities in key segments of the Global Genetic Testing Market
  • Recent developments

Frequently Asked Questions (FAQs)

Global Genetic Testing Market was valued at USD 7,902 million in 2018 and is expected to grow at a CAGR of 11.8% during the forecast period.
North America is expected to hold the highest market share in Genetic Testing Market.
In 2018 Global Genetic Testing Market was valued at USD 7,902 million.
Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Precipio, Myriad Genetics, Inc., Luminex Corporation are the top players in Genetic Testing Market.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times, and included in every purchase.

Global Statistics Representing Genetic Testing Market Scenario

Genetic testing market is majorly driven by the increasing prevalence of genetic disorders, oncology, and rare disease. Today, the growing demand for genetic data for the discovery of new therapies such as personalized medicine and targeted drugs are offering lucrative opportunities for the market growth.  

Global genetic testing market was valued at USD 7,902 million in 2018 and is expected to grow at a CAGR of 11.8% during the forecast period.

What are the benefits of genetic testing?

‘Human Genome Project’ and advancements in computer technology are unraveling umpteen underlying genes related mysteries and is paving to be a blessing in the diagnosis of life-threating diseases, including genetic mutation, and cancer, among others. In line with the growing popularity, several players  are investing heavily in the genetic diagnostic for the detection of different types of cancer. For instance, Grail—a spin-off of Illumina—is working on detecting different types of cancer with a simple blood test and has received over USD 1.5 billion funding from various sources, including renowned companies like Amazon and Microsoft. Additionally, many research institutes are actively working on developing related tests. For instance, recently, Johns Hopkins University school of medicine developed a CancerSEEK test that can detect about 8 different types of cancer.

Genetic Testing: A Beginning of Personalized Medicine Era

Today, genomic data—when integrated with data analytics tools—have the potential to fulfill the data needs for personalized medicine research. Moreover, next-generation sequencing is becoming a revolutionary technology among the academic and clinical research practices, which is further creating umpteen potential opportunities for the diagnostic test service providers and the pharmaceutical companies in discovering new therapies. For instance, 23andMe, a genomics biotechnology company, offers ancestry related tests to the customers. The company has a choice to sell this data for biomedical research. In 2018, GlaxoSmithKline plc. and 23andMe entered into an agreement to identify novel drug targets. In addition, GlaxoSmithKline plc. made an equity investment of USD 300 million in 23andMe. Similarly, Flatiron Health and Foundation Medicine’s Clinico-Genomic Database offers genomic data of over 120,000 cancer patients.  

Increasing Prevalence of Genetic Disorders

Globally, the prevalence of several rare diseases is growing at a concerning. Currently, around 400 million people are suffering from different rare diseases across the globe. As per the Global Genes, about 8 in 10 rare diseases are caused due to the faulty gene and there are around 7,000 types of rare disease and genetic disorders across the globe. In the U.K alone, about 30,000 children and babies are diagnosed with a certain type of genetic disorder, Genetic Disorders U.K. Whereas, in the U.S., birth defects affects 1 in every 33 babies (about 3% of all babies) every year. As per CDC, birth defect is one of the leading cause of infant deaths, accounting for about 20% of total infant deaths across the globe. Some of the most common inherited disorders include sickle cell disease, and thalassemia, among others. In the U.S., sickle cell disease affects around 100,000 Americans, the CDC. Its average medical expenditure is estimated to be USD 11,702, with medical coverage of USD 14,772 for children. 

Intended Audience

  • Genetic Test Manufacturers and Suppliers
  • Pharmaceutical Companies
  • Hospitals
  • Research Institutes
  • Regulatory Bodies

Diagnostic Testing to Account for a Large Share of the Pie

In the report, we have provided a detailed analysis of the genetic testing information, including carrier testing, diagnostic testing, newborn screening, and prenatal testing. The diagnostic testing captures a larger share of the global genetic testing market. This can be attributed to the increasing prevalence of genetic disorders across the globe. As per the American Society for Reproductive Medicine, birth defects are prevalent in 1 in every 20 pregnancies. That is why, the screening of the genetic diseases are performed extensively in the developed nations for reducing the prevalence of birth defects. Preimplantation genetic diagnosis is one such technique that tests embryos for genetic disorders before in vitro fertilization. In line with this, several market players are collaborating on developing advanced preimplantation genetic diagnosis. Recently, in 2019, Vitrolife received the distribution rights of Illumina’s (PGT-A) kit VeriSeq that is used in the preimplantation genetic testing for aneuploidy. Vitrolife is targeting the Americas, Europe, and the Middle East and Africa for selling its product.

North America Will Remain the Most Prominent Market Due To Well Established Healthcare Infrastructure  

North America is dominating the global genetic testing market and will continue the same during the forecast period. This can be attributed to the well-established healthcare infrastructure, defined regulatory framework, and high adoption of genetic tests. The U.S. alone has the presence of gigantic genetic testing laboratories that are offering high-end services to the customers. Additionally, increasing partnership among the players is adding fuel to the market growth. In September 2019, ARCHIMEDlife and Blueprint Genetics partnered in North America—ARCHIMEDlife Medical Laboratory offers biochemical and genetic testing for rare diseases—to increase the range of genetic testing services in North America.  

Europe to Rank Second in the Genetic Testing Market

Europe has the second largest genetic testing market. In the region, the healthcare service varies as per the geographical coverage, population density, and government policies. The governments in the region are actively participating in increasing the adoption of genetic testing across the healthcare sector. For instance, recently, the European Commission-funded EuroGentest—a genetic testing project—that aims at standardizing the process of genetic testing, and provide high-quality, accurate, and reliable results. However, many countries are still grappling with strict regulations of genetic testing. For instance, Germany’s Genetic Diagnostics Act regulates both predictive and diagnostic genetic testing. Furthermore, the involvement of physicians is required for direct to home genetic services (DTC GT), the European Academies Science Advisory Council (EASAC). Globally, the changing regulatory scenario and increasing government participation for the promotion of genetic testing are driving the market growth. For instance, France and the U.K.  are planning to build sequencing facilities, and are creating databases for integrating the genetic testing results into healthcare. Recently, the U.K. announced to sequence around 5 million genomes in the next five years. In addition to this, around 13 new centers were launched in the U.K. in 2019, which offered whole-genome sequencing for people suffering from cancer and autism.

Genetic Testing Industry  is Growing in Asia-Pacific  

In Asia Pacific, Japan is leading the genetic testing industry. The country’s genetic industry is backed with the presence of personalized nutrition firms that are offering several tailored products for the elderly population. The GENESIS HEALTHCARE and Genequest Inc. are two dominating companies in the genetic testing industry. Moreover, the number of newborns with birth defects has increased subsequently in the last few years, which is further adding fuel to the market growth. For instance, birth defects in Thailand, Indonesia, and India accounts for around 21%, 19%, and 19.5% , respectively.

Key Players

Some of the key players in the global genetic testing market are Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Precipio, Myriad Genetics, Inc., Luminex Corporation, F. Hoffmann-La Roche Ltd, Danaher, Bio-Rad Laboratories, Inc.,  Abbott, and 23andMe, Inc.

Global Genetic Testing  Market: Segmentation

By Type

  • Carrier Testing
  • Diagnostic Testing
  • Newborn Screening
  • Predictive and Presymptomatic Testing
  • Prenatal Testing
  • Other Types

By Technology

  • Cytogenetic Testing
  • Biochemical Testing
  • Molecular Testing

By Application

  • Alzheimer’s Disease
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Duchenne Muscular Dystrophy
  • Thalassemia
  • Huntington’s Disease
  • Rare Diseases
  • Other Diseases

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

What the Report Covers

  • In-depth analysis of market dynamics, including drivers, restraints, and opportunities
  • Quantitative analysis of the current market
  • Prevailing market opportunities in key segments of the Global Genetic Testing Market
  • Recent developments

Frequently Asked Questions (FAQs)

Global Genetic Testing Market was valued at USD 7,902 million in 2018 and is expected to grow at a CAGR of 11.8% during the forecast period.
North America is expected to hold the highest market share in Genetic Testing Market.
In 2018 Global Genetic Testing Market was valued at USD 7,902 million.
Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN, Precipio, Myriad Genetics, Inc., Luminex Corporation are the top players in Genetic Testing Market.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times, and included in every purchase.